Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery

Mol Cancer. 2024 Oct 1;23(1):218. doi: 10.1186/s12943-024-02136-2.

Abstract

Hepatic, biliary, and pancreatic cancer pose significant challenges in the field of digestive system diseases due to their highly malignant nature. Traditional Chinese medicine (TCM) has gained attention as a potential therapeutic approach with long-standing use in China and well-recognized clinical benefits. In this review, we systematically summarized the clinical applications of TCM that have shown promising results in clinical trials in treating hepatic, biliary, and pancreatic cancer. We highlighted several commonly used TCM therapeutics with validated efficacy through rigorous clinical trials, including Huaier Granule, Huachansu, and Icaritin. The active compounds and their potential targets have been thoroughly elucidated to offer valuable insights into the potential of TCM for anti-cancer drug discovery. We emphasized the importance of further research to bridge the gap between TCM and modern oncology, facilitating the development of evidence-based TCM treatment for these challenging malignancies.

Keywords: Biliary cancer; Chinese medicine; Clinical trials; Drug discovery; Liver cancer; Pancreatic cancer.

Publication types

  • Review

MeSH terms

  • Animals
  • Biliary Tract Neoplasms / drug therapy
  • Biliary Tract Neoplasms / metabolism
  • Biliary Tract Neoplasms / pathology
  • Drug Discovery*
  • Drugs, Chinese Herbal* / pharmacology
  • Drugs, Chinese Herbal* / therapeutic use
  • Humans
  • Liver Neoplasms* / drug therapy
  • Liver Neoplasms* / metabolism
  • Liver Neoplasms* / pathology
  • Medicine, Chinese Traditional* / methods

Substances

  • Drugs, Chinese Herbal